Position in AZN
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$368,760,574
New position
Shares Held
1,869,793
first reported quarter
Ownership
0.121%
of shares outstanding
% of Portfolio
0.29%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Derivatives in AZN
reported options exposure · as of Mar 31, 2026CallValue
$125,629,140
CallShares
637,000
PutValue
$24,839,859
PutShares
125,950
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Drug Manufacturers - General
Healthcare · as of Mar 31, 2026CITADEL ADVISORS LLC holds $2,757,631,879 across 16 Drug Manufacturers - General names. AZN ranks #4 (13.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | GILD |
Gilead Sciences, Inc.
|
3,982,185 | $554,997,122 | |
| 2 | JNJ |
Johnson & Johnson
|
1,930,976 | $472,007,773 | |
| 3 | MRK |
Merck & Co., Inc.
|
3,821,227 | $459,655,395 | |
| 4 | AZN |
Astrazeneca PLC
This page
|
1,869,793 | $368,760,574 | |
| 5 | LLY |
ELI LILLY & Co
|
241,714 | $222,321,285 | |
| 6 | PFE |
Pfizer Inc
|
7,359,865 | $206,665,008 | |
| 7 | ABBV |
AbbVie Inc.
|
490,285 | $106,632,084 | |
| 8 | NVO |
Novo Nordisk A S
|
2,736,525 | $100,567,293 |
All Filings in AZN
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $24,839,859 | 125,950 | Put | Defined | 2026-05-15 | |
| 2026-03-31 | $125,629,140 | 637,000 | Call | Defined | 2026-05-15 | |
| 2026-03-31 | $368,760,574 | 1,869,793 | Shares | Defined | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||